Odycell

Odycell is developing a novel nanotherapy to transform solid tumor treatment and has shown complete tumor regression within 4 days in preclinical murine models. Its Ithaca nanoparticle platform converts immune-excluded tumors into immune-active tumors. Ithaca is an in vivo platform: following administration, immune cells transport the nanoparticles directly to the tumor, where they reprogram tumor-associated macrophages, enhance immune infiltration, and induce immunogenic cell death. The initial focus is NSCLC, the leading cause of cancer-related death worldwide, but its modular architecture enables expansion across multiple oncology indications using the same technology base. Current treatment options remain insufficient. Cell therapies can exceed $400K per treatment and have shown limited success in solid tumors. Checkpoint inhibitors require repeated administrations and benefit only a subset of patients, leaving the majority without durable clinical responses. Ithaca is being developed as a scalable single-dose therapy, designed to be substantially more cost-effective than current cell therapies. Odycell is pioneering a new therapeutic approach that combines nanotechnology with immune-cell-mediated delivery to reprogram the tumor ecosystem, activate systemic anti-tumor immunity, and generate durable immunological memory.